Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Cash: 2012-2024

Historic Change in Cash for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $7.3 million.

  • Amphastar Pharmaceuticals' Change in Cash rose 1044.41% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 130.69%. This contributed to the annual value of $7.3 million for FY2024, which is 161.96% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Change in Cash stood at $7.3 million for FY2024, which was up 161.96% from -$11.8 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Change in Cash peaked at $32.1 million during FY2021, and registered a low of -$11.8 million during FY2023.
  • Its 3-year average for Change in Cash is $8.4 million, with a median of $7.3 million in 2024.
  • Its Change in Cash has fluctuated over the past 5 years, first soared by 249.83% in 2020, then slumped by 139.68% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Change in Cash (Yearly) stood at $19.0 million in 2020, then spiked by 69.23% to $32.1 million in 2021, then dropped by 7.28% to $29.7 million in 2022, then tumbled by 139.68% to -$11.8 million in 2023, then skyrocketed by 161.96% to $7.3 million in 2024.